- York House Church Lane, Chalfont St Peter,
Gerrards Cross, Buckinghamshire, SL9 9RE - 666-888-0000
- info@tersanpharm.com
- info@tersanpharm.com
- York House Church Lane, Chalfont St Peter,
Gerrards Cross, Buckinghamshire, SL9 9RE - Contact Us
May2016
Tersan Science Day (Paris | May 9)
Tersan hosted their regular Science Day this week – a 1-day symposium in Paris on advances in machine learning and artificial intelligence, chaired by Dr Jean Sallantin, Director of Research at the CNRS LIRMM (Laboratoire d’Informatique, de Robotique et de Micro-électronique de Montpellier) and Scientific Advisor to Tersan. As ever, this was a stimulating […]
Apr2016
NoFinishLine Paris 2016 (Paris | April 13)
The Tersan Running Team are pleased to participate in the popular NoFinishLine Paris 2016 charitable fun run event in support of sick and homeless children. Tersan Running Team at NoFinishLine Paris 2016 (Left to right): Sébastien Vaucouleur, Isabelle Chaduteau, Dan Manak, Mohammad Afshar, Yannic Tognetti, Frédéric Parmentier (11254), David Morley, Vincent Récamier, Julie Miralves, […]
Jun2015
WIN 2015 Symposium (Paris | 29-30 June)
Dr Mohammad Afshar (Founder and CEO) is presenting our Onco KEM® platform at WIN 2015 on 29 June. Dr. Mariana Guergova-Kuras (CTO) and Dr David Morley (VP Computational Technology) will also be attending the symposium for a fascinating two days of cutting-edge presentations and discussions with global key opinion leaders in cancer research and precision cancer […]
Jun2015
Tersan® Pharma teams together with SIB Swiss Institute of Bioinformatics to discover novel biomarkers for gastric cancer
Leader in clinical big data analytics collaborates with world-class bioinformatics provider in GastricGlycoExplorer consortiumPartnership to develop early detection tools for one of the deadliest cancers Links: Download English PDF | Download French PDF Paris, France, Cambridge, Massachusetts USA, and Geneva, Switzerland, 1 June 2015 – Tersan Pharmaceuticals Ltd, developer of innovative clinical data analysis and diagnostic […]
Jan2015
Nabsys and Tersan Pharmaceuticals Ltd Collaborate to Identify DNA Structural Variants Linked to Targeted Cancers
Nabsys will collaborate with Tersan Pharmaceuticals Ltd to identify structural variations related to breast and prostate cancer and how they affect clinical outcome of patients. Links: Download English PDF Providence, Rhode Island, USA, and Paris, FRANCE – January 12th , 2015 – Nabsys, Inc., a life sciences company pioneering semiconductor-based tools for human genomic analysis in […]
Dec2014
Onco KEM(R) platform for personalized cancer treatment selection
Tersan Pharmaceuticals Ltd releases a video to illustrate its innovative Onco KEM® platform for personalized cancer treatment selection. Onco KEM® intends to accelerate the translation of personalized medicine discoveries into widely available new standards of care for all cancer patients, leading to significantly improved clinical outcomes and a higher quality of life for cancer patients. […]
Dec2014
Colloque scientifique annuel du Technion (Paris | December 15)
Dr Mohammad Afshar (Founder and CEO) is joining a prestigious panel of industry leaders to discuss the strategy of open data, data intelligence and data management. Genevieve Fioraso, France’s Deputy Minister for Higher Education & Research and Axelle Lemaire, Deputy Minister in charge of digital tech will participate in the session. Making Sense of BIG […]
Dec2014
GEN corporate profile: Tersan’s Analytics Aim at Predictive Power
Specialist Company Strives to Improve Patient Selection and Treatment Outcomes. Tersan Pharmaceuticals Ltd exhaustively mines and analyzes multiparametric data (biochemical, genomic, proteomic, genetic, metabolic, imaging, clinical, etc.) to identify patient responders and reduce clinical and drug development risks. The process generates actionable information using fewer biomarker signatures than traditional data-mining methods, improving both efficiency and efficacy. […]
Oct2014
Tersan Pharmaceuticals Ltd joins the WIN Consortium as official technology partner
Leader in clinical big data analytics collaborates with global stakeholders in personalized cancer medicine. Partnership to accelerate translation of personalized medicine discoveries into widely available new standards of care for all cancer patients. Links: Download English PDF | Download French PDF Paris, France, and Cambridge, Massachusetts USA, 29 October 2014 – Tersan Pharmaceuticals Ltd, developer of […]
Jul2014
EACR-23: Shorter multimarker signatures: a new tool to facilitate cancer diagnosis
KEM® Biomarker case study presented at EACR-23 this week showed that prognostic signatures generated by KEM® Biomarker have better or similar performances to other classification methods in terms of sensitivity and specificity while having significantly lower number of features in the models. 23rd Biennial Congress of the European Association for Cancer Research. From Basic Research […]